KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Work In Process (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Work In Process for 17 consecutive years, with $904.0 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 7.62% to $904.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $904.0 million through Dec 2025, up 7.62% year-over-year, with the annual reading at $904.0 million for FY2025, 7.62% up from the prior year.
  • Work In Process hit $904.0 million in Q4 2025 for Abbott Laboratories, down from $961.0 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $962.0 million in Q2 2025 to a low of $680.0 million in Q4 2022.
  • Historically, Work In Process has averaged $816.2 million across 5 years, with a median of $823.5 million in 2023.
  • Biggest five-year swings in Work In Process: rose 25.69% in 2021 and later fell 10.8% in 2022.
  • Year by year, Work In Process stood at $694.0 million in 2021, then decreased by 2.02% to $680.0 million in 2022, then rose by 18.68% to $807.0 million in 2023, then rose by 4.09% to $840.0 million in 2024, then rose by 7.62% to $904.0 million in 2025.
  • Business Quant data shows Work In Process for ABT at $904.0 million in Q4 2025, $961.0 million in Q3 2025, and $962.0 million in Q2 2025.